Cardiff Oncology Inc
Company Profile
Business description
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
Contact
11055 Flintkote Avenue
San DiegoCA92121
USAT: +1 858 952-7570
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
31
Stocks News & Analysis
stocks
The 10 best US companies to invest in now
stocks
Surge in combat drones drives upgrade for ASX share
stocks
Meta: Meta launches enterprise offering to open up another way to monetize AI investments
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,859.20 | 4.50 | 0.05% |
| CAC 40 | 7,838.94 | 58.25 | -0.74% |
| DAX 40 | 25,283.19 | 51.99 | 0.21% |
| Dow JONES (US) | 51,089.34 | 87.62 | -0.17% |
| FTSE 100 | 10,504.40 | 42.45 | 0.41% |
| HKSE | 24,040.34 | 68.05 | 0.28% |
| NASDAQ | 27,365.87 | 175.00 | 0.64% |
| Nikkei 225 | 69,946.86 | 1,637.40 | 2.40% |
| NZX 50 Index | 13,699.02 | 18.53 | 0.14% |
| S&P 500 | 7,751.21 | 28.49 | 0.37% |
| S&P/ASX 200 | 8,686.40 | 4.30 | 0.05% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |